https://www.genearc.cn/topic/breast-cancer-her2-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/colorectal-cancer-msi-h-immunotherapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/egfr-19del-vs-l858r-evidence 2026-09-03T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/her2-erbb2-targeted-therapy-guide 2026-09-03T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/melanoma-braf-v600e-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/met-amplification-tki-combination-evidence 2026-09-03T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/ngs-report-interpretation-guide 2026-09-03T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-alk-fusion-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-colorectal-kras-g12c-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-egfr-exon20ins-targeted-therapy 2026-09-03T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-egfr-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-met-exon14-skip-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-ros1-fusion-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/nsclc-thyroid-ret-fusion-targeted-therapy 2026-08-20T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/osimertinib-resistance-evidence-guide 2026-09-03T00:00:00.000Z weekly 0.9 https://www.genearc.cn/topic/pan-cancer-ntrk-fusion-evidence-guide 2026-09-03T00:00:00.000Z weekly 0.9